M J Westerouen van Meeteren1, B Hayee2, A Inderson1, A E van der Meulen1, R Altwegg3, B van Hoek1, G P Pageaux3, T Stijnen4, D Stein5, P W J Maljaars1. 1. Leiden University Medical Centre, Department of Gastroenterology-Hepatology, Leiden, The Netherlands. 2. King's College Hospital, Department of Gastroenterology, London, UK. 3. University Hospital of St Eloi, Department of Hepatology and Gastroenterology, Montpellier, France. 4. Leiden University Medical Centre, Department of Medical Statistics, Leiden, The Netherlands. 5. Medical College of Wisconsin, Department of Gastroenterology and Hepatology, Milwaukee, WI, USA.
Abstract
BACKGROUND AND AIM: Little is known about the risk of serious infection when combining anti-tumour necrosis factor [TNF] therapy for refractory inflammatory bowel disease [IBD] with immunosuppression after liver transplantation [LT]. Our aim was to investigate the infection risk in this patient group by systematic review and meta-analysis of the available data. METHODS: A search was conducted for full papers and conference proceedings through September 2015, regarding liver transplant recipients and anti-TNF therapy. All studies were appraised using the adapted Newcastle-Ottawa Scale [NOS]. Two reviewers independently extracted patient data [age, duration of follow-up, number of all infections, number of serious infections, time since transplant]. As an additional control population, primary sclerosing cholangitis [PSC]-IBD patients from the Leiden University Medical Center [LUMC] LT cohort were used. Poisson regression was used to compare serious infections (according to International Conference on Harmonisation [ICH] definition) per patien-year follow-up between the anti-TNF and control groups. RESULTS: In all 465 articles and abstracts were identified, of which eight were included. These contained 53 post-LT patients on anti-TNF therapy and 23 post-LT patients not exposed to anti-TNF therapy. From the LUMC LT-cohort, 41 PSC patients with PSC-IBD not exposed to anti-TNF therapy were included as control population. The infection rate for TNF-exposed patients was 0.168 serious infections per patient year, compared with 0.149 in the control patients (rate ratio 1.12 [95% confidence interval: 0.233-5.404, P = 0.886]. When correcting for time since transplant, the infection rate was 0.194 in the TNF-exposed vs 0.115 in the non-exposed [p = 0.219]. CONCLUSIONS: No significant increase in the rate of serious infection was observed in LT recipients with PSC-IBD during exposure to anti-TNF therapy.
BACKGROUND AND AIM: Little is known about the risk of serious infection when combining anti-tumour necrosis factor [TNF] therapy for refractory inflammatory bowel disease [IBD] with immunosuppression after liver transplantation [LT]. Our aim was to investigate the infection risk in this patient group by systematic review and meta-analysis of the available data. METHODS: A search was conducted for full papers and conference proceedings through September 2015, regarding liver transplant recipients and anti-TNF therapy. All studies were appraised using the adapted Newcastle-Ottawa Scale [NOS]. Two reviewers independently extracted patient data [age, duration of follow-up, number of all infections, number of serious infections, time since transplant]. As an additional control population, primary sclerosing cholangitis [PSC]-IBD patients from the Leiden University Medical Center [LUMC] LT cohort were used. Poisson regression was used to compare serious infections (according to International Conference on Harmonisation [ICH] definition) per patien-year follow-up between the anti-TNF and control groups. RESULTS: In all 465 articles and abstracts were identified, of which eight were included. These contained 53 post-LT patients on anti-TNF therapy and 23 post-LT patients not exposed to anti-TNF therapy. From the LUMC LT-cohort, 41 PSC patients with PSC-IBD not exposed to anti-TNF therapy were included as control population. The infection rate for TNF-exposed patients was 0.168 serious infections per patient year, compared with 0.149 in the control patients (rate ratio 1.12 [95% confidence interval: 0.233-5.404, P = 0.886]. When correcting for time since transplant, the infection rate was 0.194 in the TNF-exposed vs 0.115 in the non-exposed [p = 0.219]. CONCLUSIONS: No significant increase in the rate of serious infection was observed in LT recipients with PSC-IBD during exposure to anti-TNF therapy.
Authors: Marco Spadaccini; Alessio Aghemo; Flavio Caprioli; Ana Lleo; Federica Invernizzi; Silvio Danese; Maria F Donato Journal: United European Gastroenterol J Date: 2019-06-20 Impact factor: 4.623
Authors: Julie J Hong; Edward K Hadeler; Megan L Mosca; Nicholas D Brownstone; Tina Bhutani; Wilson J Liao Journal: J Psoriasis Psoriatic Arthritis Date: 2022-01-12
Authors: Ming-Hsi Wang; Omar Y Mousa; Jessica J Friton; Laura E Raffals; Jonathan A Leighton; Shabana F Pasha; Michael F Picco; Kelly C Cushing; Kelly Monroe; Billy D Nix; Rodney D Newberry; William A Faubion Journal: Inflamm Bowel Dis Date: 2020-04-11 Impact factor: 5.325
Authors: Felix Poppelaars; Mariana Gaya da Costa; Bernardo Faria; Siawosh K Eskandari; Marc A Seelen; Jeffrey Damman Journal: J Inflamm Res Date: 2022-04-05
Authors: Fotios S Fousekis; Vasileios I Theopistos; Ioannis V Mitselos; Alexandros Skamnelos; Athanasios Kavvadias; Konstantinos H Katsanos; Dimitrios K Christodoulou Journal: J Clin Med Res Date: 2019-01-05